Oaktree Acquisition Corp. III Life Sciences
NASDAQ:OACCShell Companies
+$0.00 today
- Market cap
- $263.53M
- Beta
- -0.04
- P/E (TTM)
- 29.1
- EPS (TTM)
- $0.37
Volume 0.00M
Average 0.01M
OACC EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Oaktree Acquisition Corp. III Life SciencesNASDAQ: OACC
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA turns negative
Q1 FY2026 EBITDA was -$456.54K, compared with $1.66M a year earlier. Trailing-twelve-month EBITDA was -$1.21M.
What to watch
Whether quarterly EBITDA holds near -$456.54K or moves back toward the trailing-twelve-month quarterly average of -$301.86K.
Sources:Income StatementText generated from reported figures; not investment advice.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (1.2M) USD
- Year-over-year change
- -239.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.2M) | -239.9% |
| FY2024 | 2024-12-31 | (351.81K) | — |
EBITDA vs competitors
How OACC compares with its peers on the latest reported figures
- OACC's LTM Mar 2026 EBITDA of -$1.21M is the 3rd highest of the 10 companies compared; the peer median is -$1.58M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.78M | — | — | — | |
COPLCopley Acquisition Corp | LTM Mar 2026 | -$85.88K | — | — | — |
OACCOaktree Acquisition Corp. III Life Sciences | LTM Mar 2026 | -$1.21M | — | — | — |
| LTM Mar 2026 | -$1.37M | -251.8% | — | — | |
| LTM Mar 2026 | -$1.56M | — | — | — | |
| LTM Mar 2026 | -$1.58M | +79.1% | — | — | |
| LTM Mar 2026 | -$1.95M | — | — | — | |
| LTM Mar 2026 | -$2.18M | — | — | — | |
AACBArtius II Acquisition Inc. Class A Ordinary Shares | LTM Mar 2026 | -$3.62M | — | — | — |
MBAVM3-Brigade Acquisition V Corp. Class A Ordinary shares | LTM Mar 2026 | -$7.3M | -1097.6% | — | — |
| Peer median (excluding OACC) | -$1.58M | -251.8% | — | — | |
Competitors are the stored peer set for OACC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | 0 | 0 |
| Gross Profit | 0 | 0 |
| Gross Margin | — | — |
| Research & Development | 0 | 0 |
| Selling, General & Admin | 704 | 1.2M |
| Operating Expenses | 704 | 1.2M |
| Depreciation & Amortization | 704 | 0 |
| EBITDA | (351.81K) | (1.2M) |
| EBITDA Margin | — | — |
| Operating Income | (703) | (1.2M) |
| Operating Margin | — | — |
| Interest Income | 1.59M | 8.48M |
| Interest Expense | 0 | 0 |
| Other Income / Expenses | 3.37K | 8.48M |
| Income Before Tax | 2.66K | 7.29M |
| Pre-Tax Margin | — | — |
| Income Tax Expense | 0 | 0 |
| Net Income | 2.66K | 7.29M |
| Net Margin | — | — |
| EPS (Basic) | 0.05 | 0.30 |
| EPS (Diluted) | 0.05 | 0.30 |
| Weighted Avg Shares | 24.58M | 19.2M |
| Weighted Avg Shares (Diluted) | 24.58M | 19.2M |
Oaktree Acquisition Corp. III Life Sciences
NASDAQ:OACC
Intrinsic Alpha fair value
Locked
Current Price
$10.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.